SCHEMBL1380467

SCHEMBL1380467

CCCN(CCC)CC(N)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.42
CA9 Q16790 3/20 0.42
CA2 P00918 2/20 0.42
TSHR P16473 2/20 0.36
CHRM2 P08172 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
CYP2C19 P33261 2/20 0.36
ALOX15 P16050 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
ADRA2A P08913 1/20 0.36
DRD1 P21728 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
DRD3 P35462 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8416737 0.90 CA12 (0.39) CA12CA9CA2TSHRCHRM2
SCHEMBL8386144 0.89 CES2 (0.39) CA12CA9CA2CYP2C19KDM4E
SCHEMBL15809341 0.87 CES2 (0.41) CA12CA2CYP2C19KDM4ECES2
SCHEMBL1777056 0.85 CA1 (0.46) CA12CA9CA2CHRM2CYP2C19
SCHEMBL28420309 0.83 CES2 (0.42) CA12CA9CYP2C19KDM4ECES2
SCHEMBL8373313 0.83 CYP1A2 (0.42) CA12CA9CA2TSHRCHRM2
SCHEMBL22212238 0.83 CA12 (0.38) CA12CA9CA2CA1MAPK1
SCHEMBL29953434 0.83 CA12 (0.34) CA12CA9CA2CYP2C19CA1
SCHEMBL13270009 0.81 CES2 (0.44) CA12CA9CA2CYP2C19KDM4E
SCHEMBL4210961 0.81 CES2 (0.44) CA12CA9CA2CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US claimed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US claimed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP claimed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US claimed
JP-4805909-B2 2011-11-02 JP claimed
US-7723385-B2 Aniline derivatives as selective androgen receptor modulators GLAXOSMITHKLINE LLC (US) 2010-05-25 US claimed
US-20090163588-A1 ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-25 US claimed
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 US claimed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 EP claimed
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
US-7723385-B2 Aniline derivatives as selective androgen receptor modulators GLAXOSMITHKLINE LLC (US) 2010-05-25 US disclosed
US-20090163588-A1 ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-25 US disclosed
US-7176227-B2 For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis KUREHA CORPORATION (JP) 2007-02-13 US disclosed
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 US disclosed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165063-A1 Amine compounds and use thereof NR0B2, NR5A2, NR1H4 CA12 2976/4885CA9 4304/4885CA2 4598/4885
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 CA12 4166/4885CA9 3879/4885CA2 4296/4885
US-20090163588-A1 ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, NR3C2, NR5A1 CA12 4250/4885CA9 3779/4885CA2 4089/4885
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 CA12 4166/4885CA9 3879/4885CA2 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.